A Randomized, Double-blind, Single-dose, Parallel Two-arm Study to Compare the Pharmacokinetics and Safety of BAT1706 Injection From Different Manufacturing Batches (by New Process and Old Process) in Healthy Subjects

Bio-Thera Solutions1 site in 1 country38 target enrollmentJune 2023

ConditionsHealthy Men

InterventionsBAT1706 Injection

DrugsBAT1706 Injection

Overview

Phase: Phase 1
Intervention: BAT1706 Injection
Conditions: Healthy Men
Sponsor: Bio-Thera Solutions
Enrollment: 38
Locations: 1
Primary Endpoint: AUC0-inf
Status: Not yet recruiting
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is a randomized, double-blind, single-dose, parallel two-arm study to compare the pharmacokinetics, safety, and immunogenicity of BAT1706 Injection from different manufacturing batches (by new process and old process) in healthy male subjects.

Detailed Description

A total of 38 subjects are planned to be enrolled and randomized in a 1: 1 ratio to receive a single intravenous drip of BAT1706 Injection (by old process) or BAT1706 Injection (by new process) at 1 mg/kg body weight. A 7-day screening period will be set up for this study. Subjects will be admitted to the hospital 1 day pre-dose (Day -1) and discharged after completing relevant observations and assessments 24 h post-dose. After discharge, subjects should return to the hospital for 12 follow-up visits according to the requirements of this study, on Days 3, 4, 5, 8, 11, 15, 22, 29, 36, 43, 57 and 71 post-dose.

Registry

clinicaltrials.gov

Start Date

June 2023

End Date

January 2024

Last Updated

2 years ago

Study Type

Interventional

Study Design

Parallel

Sex

Male

Investigators

Sponsor

Bio-Thera Solutions

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Healthy male subjects aged between 18 and 45 years with body mass index (BMI) between 18.0 and 28.0 kg/m2 and body weight between 50 and 100 kg (inclusive);
•Subjects for whom the results of physical examination, vital signs, 12-lead ECG, and laboratory tests are normal or abnormal without clinical significance;
•Subjects who do not smoke, or smoke no more than 5 cigarettes per day for \< 10 years;
•Subjects who agree to use effective contraception (including but not limited to: hormonal contraception, physical contraception, or abstinence) from the time of signing the informed consent form until 6 months after intravenous drip of the study drug;
•Subjects who are willing and able to follow the visits, treatments, laboratory tests, and other relevant procedures specified in this study.

Exclusion Criteria

•Subjects who have previous or current clinically significant gastrointestinal disorder (including diverticulitis, gastric ulcer), renal disorder, liver disorder, cardiovascular disorder, hematological disorder, lung disorder, nervous system disorder, metabolic disorder (including known diabetes mellitus), psychosis, or allergic disease (excluding mild asymptomatic seasonal allergy) at screening/enrollment, and in the opinion of the investigator, are not suitable for participation in this clinical study;
•Subjects who have psychiatric disorders, or in the opinion of the investigator, are not suitable for participation in this clinical study (e.g., he is considered unable to understand or follow the relevant requirements of the study, or some of his existing conditions may result in additional risks associated with participation in this study);
•Subjects who have previous or current clinically significant allergies (excluding mild asymptomatic seasonal allergy); or subjects who have known or suspected allergy or hypersensitivity to any component of the study drug; or subjects who have known or suspected hypersensitivity to Chinese hamster ovary cell products or other recombinant human or humanized antibodies;
•Subjects who have a tendency to haemorrhage or thrombosis, or have a history of non-traumatic haemorrhage with appropriate clinical treatment, or have a history of thrombosis, or have any disease that may increase the risk of haemorrhage or thrombosis (e.g., abnormal coagulation, thrombocytopenia, or INR \> 1.5);
•Subjects who have any previous malignancy including lymphoma, leukemia, and skin cancer;
•Subjects who have abnormal and clinically significant ECG (as judged by the investigator), or corrected QT interval according to Bazett's formula \> 470 ms (Bazett's formula: Q-Tc = QT/(R-R)0.5, where R-R represents the interval between two R waves in s);
•Subjects who have a history of hypertension, or systolic blood pressure \> 145 mmHg or diastolic blood pressure \> 95 mmHg at screening/enrollment;
•Subjects who have clinically significant chronic or acute infection at screening/enrollment; or have any positive result for HBV surface antigen, HCV antibody, HIV antibody, and treponema pallidum antibody at screening;
•Subjects who have previously used Bevacizumab or VEGF-targeting agents;
•Subjects who have used any biological product within 3 months prior to enrollment, or have used any monoclonal antibody within 9 months prior to enrollment;

Arms & Interventions

BAT1706（New Process）

Drug: BAT1706 1 mg/kg, the corresponding volume of bulk solution should be drawn according to the actual body weight of the subject, diluted to 100 mL with 0.9% sodium chloride solution, and administered by intravenous drip

Intervention: BAT1706 Injection